Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 3/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.36 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.36 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5078309 | 0.89 | POLB (0.37) | CACNA2D1CACNB1CACNA1BCACNA1COPRM1 | |
| SCHEMBL5081532 | 0.87 | OPRM1 (0.36) | CYP3A4CACNA2D1CACNB1CACNA1BCACNA1C | |
| SCHEMBL674830 | 0.86 | CYP2D6 (0.38) | CYP3A4CYP3A5OPRM1OPRD1KCNH2 | |
| SCHEMBL3297716 | 0.85 | CYP3A4 (0.40) | CYP3A4SCN5ASCN9AOPRM1OPRD1 | |
| SCHEMBL5078931 | 0.85 | MEN1 (0.43) | SCN5ASCN9APDE2A | |
| SCHEMBL5082053 | 0.84 | OPRM1 (0.39) | CYP3A4CACNA1ACACNA2D1CACNB1CACNA1B | |
| SCHEMBL3297436 | 0.83 | LMNA (0.40) | CYP3A4CYP3A5OPRM1OPRD1CNR1 | |
| SCHEMBL6903343 | 0.82 | CYP3A4 (0.31) | CYP3A4CYP3A5OPRM1OPRD1 | |
| SCHEMBL7085994 | 0.82 | CYP3A4 (0.31) | CYP3A4CYP3A5OPRM1OPRD1 | |
| SCHEMBL6903888 | 0.82 | CYP3A4 (0.31) | CYP3A4CYP3A5OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107356-A1 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2005-05-19 | — | — | US | claimed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | claimed |
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2004-11-25 | — | — | US | claimed |
| EP-1328269-B1 | ASSOCIATION OF A CB1 RECEPTOR ANTAGONIST AND SIBUTRAMIN FOR TREATING OBESITY | AVENTIS PHARMA SA (FR) | 2004-05-26 | — | — | EP | claimed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | claimed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | claimed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | claimed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | claimed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | claimed |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2008-03-06 | — | — | US | disclosed |
| US-7148258-B2 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2006-11-30 | — | — | US | disclosed |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | AVENTIS PHARMA S.A. (FR) | 2006-11-16 | — | — | US | disclosed |
| US-7105504-B2 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | AVENTIS PHARMA S.A. (FR) | 2006-09-12 | — | — | US | disclosed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | disclosed |
| US-6518264-B2 | For treatment/prevention of psychoses, other brain disorders, and cardiovascular disorders | AVENTIS PHARMA S.A. (FR) | 2003-02-11 | — | — | US | disclosed |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | AVENTIS PHARMA S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2002-03-21 | — | — | US | disclosed |
| EP-1112251-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000015609-A1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235816-A1 | Azetidine derivatives, their preparation and medicaments containing them | AZI2, ADRA2A, ADRA2C | CYP3A4 68/4885CYP3A5 62/4885SCN5A 161/4885 |
| US-20080058381-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP3A5 720/4885SCN5A 503/4885 |
| US-20060270649-A1 | AZETIDINE DERIVATIVES, THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | AZI2, QDPR, ADRA2A | CYP3A4 71/4885CYP3A5 46/4885SCN5A 177/4885 |
| US-20060258709-A1 | COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF OBESITY | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP3A5 720/4885SCN5A 503/4885 |
| US-20020091114-A1 | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity | CNR2, CNR1, GPR119 | CYP3A4 1369/4885CYP3A5 720/4885SCN5A 503/4885 |
| US-20050107356-A1 | Combination of a CB1 receptor antagonist and of a product which activates dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | CNR1, CNR2, GPR18 | CYP3A4 2489/4885CYP3A5 2608/4885SCN5A 1660/4885 |
| US-20020035102-A1 | Azetidine derivatives, their preparation and medicaments containing them | CYP11B2, AZI2, CYP2C19 | CYP3A4 15/4885CYP3A5 75/4885SCN5A 2140/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | CYP3A4 40/4885CYP3A5 22/4885SCN5A 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.